Revvity (RVTY) Liabilities from Discontinued Operations (2010 - 2023)
Revvity's (RVTY) quarterly Liabilities from Discontinued Operations came in at $272.9 million in Q1 2023, up 32.72% on a YoY basis from $205.6 million in Q1 2022, and up 16.22% quarter-over-quarter from $234.8 million in Q4 2022.
Analysis
Revvity (RVTY) Liabilities from Discontinued Operations (2010 - 2023) Analysis & Trends
Revvity (RVTY) has reported Liabilities from Discontinued Operations for 14 consecutive years, with $272.9 million the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Liabilities from Discontinued Operations rose 32.72% year-over-year to $272.9 million; the trailing twelve-month figure through Jan 2023 stood at $272.9 million (up 32.72% YoY), and the FY2023 full-year result was $272.9 million, up 32.72% from the prior year.
- Liabilities from Discontinued Operations advanced to $272.9 million in Q1 2023 per RVTY's latest filing, from $234.8 million in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at $272.9 million in Q1 2023 and bottomed at $2.1 million in Q3 2020.
- Historically, Liabilities from Discontinued Operations has averaged $66.4 million across 5 years, with a median of $2.1 million in 2019.
- The sharpest annual moves came in 2019 and 2022: Liabilities from Discontinued Operations slipped 2.45% in 2019, then surged 9361.3% in 2022.
- Over 5 years, Liabilities from Discontinued Operations stood at $2.1 million in 2019, then dropped by 0.71% to $2.1 million in 2020, then rose by 3.62% to $2.2 million in 2021, then soared by 10704.79% to $234.8 million in 2022, then grew by 16.22% to $272.9 million in 2023.
- According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered $272.9 million, $234.8 million, and $205.6 million for Q1 2023, Q4 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jan 1, 2023 | 272.87 Mn |
| Oct 2, 2022 | 234.79 Mn |
| Jan 2, 2022 | 205.59 Mn |
| Jan 3, 2021 | 2.17 Mn |
| Oct 4, 2020 | 2.10 Mn |
| Jul 5, 2020 | 2.10 Mn |
| Apr 5, 2020 | 2.11 Mn |
| Dec 29, 2019 | 2.11 Mn |
| Sep 29, 2019 | 2.11 Mn |
| Jun 30, 2019 | 2.13 Mn |
| Mar 31, 2019 | 2.13 Mn |
| Dec 30, 2018 | 2.17 Mn |
| Sep 30, 2018 | 2.17 Mn |
| Jul 1, 2018 | 2.17 Mn |
| Apr 1, 2018 | 2.15 Mn |
| Dec 31, 2017 | 2.10 Mn |
| Oct 1, 2017 | 2.15 Mn |
| Jul 2, 2017 | 6.37 Mn |
| Apr 2, 2017 | 46.22 Mn |
| Jan 1, 2017 | 41.93 Mn |